BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cariello M, Piccinin E, Moschetta A. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. Cell Mol Gastroenterol Hepatol 2021;11:1519-39. [PMID: 33545430 DOI: 10.1016/j.jcmgh.2021.01.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou LM, Fan JH, Xu MM, Xiong MY, Wang QJ, Chai X, Li XD, Li XG, Ye XL. Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis. Biochim Biophys Acta Mol Basis Dis 2023;:166639. [PMID: 36638873 DOI: 10.1016/j.bbadis.2023.166639] [Reference Citation Analysis]
2 Lizard G, Mackrill JJ, Willinger T. Implication of Oxysterols in Infectious and Non-Communicable Inflammatory Diseases. Cells 2023;12. [PMID: 36672175 DOI: 10.3390/cells12020241] [Reference Citation Analysis]
3 Chen JYS, Chua D, Lim CO, Ho WX, Tan NS. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. Int J Mol Sci 2022;24. [PMID: 36613602 DOI: 10.3390/ijms24010158] [Reference Citation Analysis]
4 Rausch M, Samodelov SL, Visentin M, Kullak-Ublick GA. The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity. Int J Mol Sci 2022;23. [PMID: 36430444 DOI: 10.3390/ijms232213967] [Reference Citation Analysis]
5 Tang K, Kong D, Peng Y, Guo J, Zhong Y, Yu H, Mai Z, Chen Y, Chen Y, Cui T, Duan S, Li T, Liu N, Zhang D, Ding Y, Huang J. Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1000444] [Reference Citation Analysis]
6 Kim N, Lim C, Park H, Kim J, Pham T, Yang Y, Lee HP, Hong JT, Yoon D. MMPP promotes adipogenesis and glucose uptake via binding to the PPARγ ligand binding domain in 3T3-L1 MBX cells. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.994584] [Reference Citation Analysis]
7 Zhang Z, Chen D, Yu J, Su X, Li L. Metabolic perturbations in human hepatocytes induced by bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate exposure: Insights from high-coverage quantitative metabolomics. Anal Biochem 2022;657:114887. [PMID: 36150471 DOI: 10.1016/j.ab.2022.114887] [Reference Citation Analysis]
8 Duan J, Huang Z, Nice EC, Xie N, Chen M, Huang C. Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. J Adv Res 2022:S2090-1232(22)00188-6. [PMID: 35973552 DOI: 10.1016/j.jare.2022.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zhang M, Zhou Y, Xie Z, Luo S, Zhou Z, Huang J, Zhao B. New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes. Front Endocrinol (Lausanne) 2022;13:914136. [PMID: 35757405 DOI: 10.3389/fendo.2022.914136] [Reference Citation Analysis]
10 Vijayakumar A, Okesli-Armlovich A, Wang T, Olson I, Seung M, Kusam S, Hollenback D, Mahadevan S, Marchand B, Toteva M, Breckenridge DG, Trevaskis JL, Bates J. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatol Commun 2022. [PMID: 35735253 DOI: 10.1002/hep4.2011] [Reference Citation Analysis]
11 Torres S, Segalés P, García-Ruiz C, Fernández-Checa JC. Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Cells 2022;11:1475. [PMID: 35563780 DOI: 10.3390/cells11091475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Li G, Li X, Yang L, Wang S, Dai Y, Fekry B, Veillon L, Tan L, Berdeaux R, Eckel-Mahan K, Lorenzi PL, Zhao Z, Lehner R, Sun K. Adipose tissue-specific ablation of Ces1d causes metabolic dysregulation in mice. Life Sci Alliance 2022;5:e202101209. [PMID: 35459739 DOI: 10.26508/lsa.202101209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zhou W, Anakk S. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. Mol Cell Endocrinol 2022;:111616. [PMID: 35304191 DOI: 10.1016/j.mce.2022.111616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
15 Quinn C, Rico MC, Merali C, Merali S. Dysregulation of S-adenosylmethionine Metabolism in Nonalcoholic Steatohepatitis Leads to Polyamine Flux and Oxidative Stress. Int J Mol Sci 2022;23:1986. [PMID: 35216100 DOI: 10.3390/ijms23041986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
16 Erb SJ, Chandler TL, White HM. Responsiveness of PNPLA3 and lipid-related transcription factors is dependent upon fatty acid profile in primary bovine hepatocytes. Sci Rep 2022;12:888. [PMID: 35042927 DOI: 10.1038/s41598-021-04755-x] [Reference Citation Analysis]
17 Li J, Denicola GM, Ruffell B. Metabolism in tumor-associated macrophages. International Review of Cell and Molecular Biology 2022. [DOI: 10.1016/bs.ircmb.2022.01.004] [Reference Citation Analysis]
18 Quinn CR, Rico MC, Merali C, Merali S. Role of glycine-N-methyl transferase in human and murine nonalcoholic steatohepatitis.. [DOI: 10.1101/2021.12.03.470998] [Reference Citation Analysis]
19 Escher SE, Aguayo-Orozco A, Benfenati E, Bitsch A, Braunbeck T, Brotzmann K, Bois F, van der Burg B, Castel J, Exner T, Gadaleta D, Gardner I, Goldmann D, Hatley O, Golbamaki N, Graepel R, Jennings P, Limonciel A, Long A, Maclennan R, Mombelli E, Norinder U, Jain S, Capinha LS, Taboureau OT, Tolosa L, Vrijenhoek NG, van Vugt-Lussenburg BMA, Walker P, van de Water B, Wehr M, White A, Zdrazil B, Fisher C. A read-across case study on chronic toxicity of branched carboxylic acids (1): Integration of mechanistic evidence from new approach methodologies (NAMs) to explore a common mode of action. Toxicol In Vitro 2021;:105269. [PMID: 34757180 DOI: 10.1016/j.tiv.2021.105269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
20 Biagioli M, Fiorucci S. Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Research 2021;5:119-41. [DOI: 10.1016/j.livres.2021.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
21 Zhou T, Kundu D, Robles-Linares J, Meadows V, Sato K, Baiocchi L, Ekser B, Glaser S, Alpini G, Francis H, Kennedy L. Feedback Signaling between Cholangiopathies, Ductular Reaction, and Non-Alcoholic Fatty Liver Disease. Cells 2021;10:2072. [PMID: 34440841 DOI: 10.3390/cells10082072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Khanam A, Saleeb PG, Kottilil S. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? Cells 2021;10:1097. [PMID: 34064375 DOI: 10.3390/cells10051097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
23 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]